320 related articles for article (PubMed ID: 15710588)
21. Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.
Tedeschi A; Ricci F; Goldaniga MC; Benevolo G; Varettoni M; Motta M; Pioltelli P; Gini G; Barate' C; Luraschi A; Vismara E; Frustaci AM; Nichelatti M; Vitolo U; Baldini L; Morra E
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):231-4. PubMed ID: 23490992
[TBL] [Abstract][Full Text] [Related]
22. Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.
Shin SJ; Chun SH; Kim KO; Kim MK; Lee KH; Hyun MS; Cho HS
Jpn J Clin Oncol; 2005 Oct; 35(10):622-5. PubMed ID: 16172172
[TBL] [Abstract][Full Text] [Related]
23. An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.
Amin CJ; Rabinowitz I
Clin Lab Haematol; 2005 Jun; 27(3):200-2. PubMed ID: 15938727
[TBL] [Abstract][Full Text] [Related]
24. Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
Johnson SA; Owen RG; Oscier DG; Leblond V; Levy V; Jaeger U; Seymour JF
Clin Lymphoma; 2005 Mar; 5(4):294-7. PubMed ID: 15794869
[TBL] [Abstract][Full Text] [Related]
25. Extramedullary, extranodal lymphoplasmacytic lymphoma with macroglobulinemia: long-term complete remission with fludarabine.
Christopoulos C; Fortis A; Tassidou A; Anevlavis E
Ann Hematol; 2008 Feb; 87(2):159-61. PubMed ID: 17724597
[No Abstract] [Full Text] [Related]
26. Fludarabine therapy in Waldenström's macroglobulinemia.
Dimopoulos MA; O'Brien S; Kantarjian H; Pierce S; Delasalle K; Barlogie B; Alexanian R; Keating MJ
Am J Med; 1993 Jul; 95(1):49-52. PubMed ID: 8328496
[TBL] [Abstract][Full Text] [Related]
27. Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia derives from an extensively hypermutated B cell that lacks ongoing somatic hypermutation.
Walsh SH; Laurell A; Sundström G; Roos G; Sundström C; Rosenquist R
Leuk Res; 2005 Jul; 29(7):729-34. PubMed ID: 15927667
[TBL] [Abstract][Full Text] [Related]
28. [Clinical pharmacology of fludarabine].
Robak T; Drzewoski J
Pol Tyg Lek; 1991 Dec 2-9; 46(48-49):942-4. PubMed ID: 1845714
[No Abstract] [Full Text] [Related]
29. Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.
Dimopoulos MA; Hamilos G; Efstathiou E; Siapkaras I; Matsouka C; Gika D; Grigoraki V; Papadimitriou C; Mitsibounas D; Anagnostopoulos N
Leuk Lymphoma; 2003 Jun; 44(6):993-6. PubMed ID: 12854900
[TBL] [Abstract][Full Text] [Related]
30. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.
Treon SP; Hunter ZR; Matous J; Joyce RM; Mannion B; Advani R; Cook D; Songer J; Hill J; Kaden BR; Sharon D; Steiss R; Leleu X; Branagan AR; Badros A
Clin Cancer Res; 2007 Jun; 13(11):3320-5. PubMed ID: 17545538
[TBL] [Abstract][Full Text] [Related]
31. The role of fludarabine in hematological malignancies.
Wright SJ; Robertson LE; O'Brien S; Plunkett W; Keating MJ
Blood Rev; 1994 Sep; 8(3):125-34. PubMed ID: 7819814
[TBL] [Abstract][Full Text] [Related]
32. Fludarabine-based combination therapies for Waldenström's macroglobulinemia.
Tedeschi A; Alamos SM; Ricci F; Greco A; Morra E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):67-70. PubMed ID: 19362977
[TBL] [Abstract][Full Text] [Related]
33. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
Konoplev S; Medeiros LJ; Bueso-Ramos CE; Jorgensen JL; Lin P
Am J Clin Pathol; 2005 Sep; 124(3):414-20. PubMed ID: 16191510
[TBL] [Abstract][Full Text] [Related]
34. Fludarabine treatment in resistant Waldenstrom's macroglobulinemia.
Zinzani PL; Gherlinzoni F; Bendandi M; Zaccaria A; Aitini E; Salvucci M; Tura S
Eur J Haematol; 1995 Feb; 54(2):120-3. PubMed ID: 7698295
[TBL] [Abstract][Full Text] [Related]
35. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
Treon SP; Hansen M; Branagan AR; Verselis S; Emmanouilides C; Kimby E; Frankel SR; Touroutoglou N; Turnbull B; Anderson KC; Maloney DG; Fox EA
J Clin Oncol; 2005 Jan; 23(3):474-81. PubMed ID: 15659493
[TBL] [Abstract][Full Text] [Related]
36. Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.
Leblond V; Ben-Othman T; Deconinck E; Taksin AL; Harousseau JL; Delgado MA; Delmer A; Maloisel F; Mariette X; Morel P; Clauvel JP; Duboisset P; Entezam S; Hermine O; Merlet M; Yakoub-Agha I; Guibon O; Caspard H; Fort N
J Clin Oncol; 1998 Jun; 16(6):2060-4. PubMed ID: 9626204
[TBL] [Abstract][Full Text] [Related]
37. Lymphoplasmacytic lymphoma with IgA hypergammaglobulinemia and liver involvement.
Polprasert C; Wongchitrat C; Assanasen T; Prayongratana K
J Med Assoc Thai; 2009 Jun; 92 Suppl 3():S65-8. PubMed ID: 19702069
[TBL] [Abstract][Full Text] [Related]
38. Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.
Keating MJ; McLaughlin P; Plunkett W; Robertson LE; O'Brien S; Gandhi V; Gregoire V; Yang L; Cabanillas F
Ann Oncol; 1994; 5 Suppl 2():79-83. PubMed ID: 8204523
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Dimopoulos MA; O'Brien S; Kantarjian H; Estey EE; Keating MJ; Alexanian R
Leuk Lymphoma; 1993; 11 Suppl 2():105-8. PubMed ID: 7907250
[TBL] [Abstract][Full Text] [Related]
40. Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies.
Johnson SA
Hematol J; 2004; 5 Suppl 1():S50-61. PubMed ID: 15079153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]